Roche Holding AG (OTCMKTS:RHHBY) Receives $40.00 Average Price Target from Analysts

Shares of Roche Holding AG (OTCMKTS:RHHBY) have received an average recommendation of “Reduce” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $40.00.

RHHBY has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. The Goldman Sachs Group began coverage on Roche in a research report on Thursday, May 30th. They set a “sell” rating for the company.

Roche Price Performance

RHHBY opened at $41.16 on Wednesday. Roche has a 1-year low of $29.20 and a 1-year high of $42.43. The company has a 50 day simple moving average of $38.78 and a two-hundred day simple moving average of $34.47. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.75.

Hedge Funds Weigh In On Roche

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AlphaMark Advisors LLC bought a new position in Roche during the first quarter valued at $34,000. First Horizon Advisors Inc. grew its position in Roche by 19.8% in the fourth quarter. First Horizon Advisors Inc. now owns 2,066 shares of the company’s stock worth $75,000 after acquiring an additional 342 shares in the last quarter. GAMMA Investing LLC increased its stake in Roche by 61.5% during the second quarter. GAMMA Investing LLC now owns 5,038 shares of the company’s stock worth $175,000 after acquiring an additional 1,919 shares during the last quarter. Archer Investment Corp raised its position in Roche by 10.6% during the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock valued at $236,000 after purchasing an additional 652 shares during the period. Finally, Waldron Private Wealth LLC bought a new stake in shares of Roche in the 2nd quarter valued at approximately $263,000.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.